Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study

Kieron Dunleavy, Michelle A. Fanale, Jeremy S. Abramson, Ariela Noy, Paolo Fabrizio Caimi, Stefania Pittaluga, Samir Parekh, Ann Lacasce, John W. Hayslip, Deepa Jagadeesh, Sunil Nagpal, Mary Jo Lechowicz, Rakesh Gaur, Andrea Lucas, Christopher Melani, Mark Roschewski, Seth M. Steinberg, Elaine S. Jaffe, Brad Kahl, Jonathan W. FriedbergRichard F. Little, Nancy L. Bartlett, Wyndham H. Wilson

Research output: Contribution to journalArticlepeer-review

88 Scopus citations

Fingerprint

Dive into the research topics of 'Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study'. Together they form a unique fingerprint.

Medicine & Life Sciences